Philippine health officials order Sanofi to halt Dengvaxia sales as controversy over health threat swells
Philippine health officials have ordered Sanofi to jerk its dengue vaccine off the market as the controversy over the health threat it poses to children continues to roil the country.
The Philippines was the first country to launch a major vaccination campaign with Dengvaxia, the world’s first dengue vaccine. But last week Sanofi conceded something that two expert groups had concluded independently just as the country was rolling out its $70 million effort early last year. The vaccine, given to anyone who had not already been infected, left people vulnerable to severe, life-threatening dengue in the event they were subsequently infected by wild type dengue.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.